Szczepionki DNA w prewencji chorob pasozytniczych: stan obecny i perspektywy

• Autorzy: Wedrychowicz H , Kofta W.
• Języki publikacji: PL

Abstrakty

EN

The introduction of genetic or "naked DNA" vaccines may open a new era in vaccinology. DNA vaccination is a relatively simple process: a recombinant vector containing cDNA of the potentially protective pathogen antigen, is delivered to a host organism under the control of a strong promoter. It has been demonstrated that the introduced DNA remains stable as an episome for a long time and does not integrate into a genome of vaccinated organism. The type of immune response elicited by DNA vaccination depends very much on the antigen used and on the way of the vaccine delivery. Generally, DNA vaccination induces Tol-dependent rather than Th2-dependent immune response. DNA vaccines present many advantages over "traditional" ones. Firstly, it is easier to obtain a considerable amount of DNA than similar quantities of purified protective antigen protein. Secondly, the antigenic proteins synthesised within the host cell possess an appropriate molecular structure and undergo a posttranslational modifications specific for the native protein. The posttranslational modifications, for example glycosylation, cannot be introduced during expression of the recombinant protein antigens in bacterial hosts.

Słowa kluczowe

PL

choroby pasozytnicze; szczepienia genetyczne; parazytologia; prewencja; immunizacja; szczepionki

• Wydawca: -
• Czasopismo: Wiadomości Parazytologiczne
• Rocznik: 1998
• Tom: 44
• Numer: 2
• Opis fizyczny: s.175-180, bibliogr.

Twórcy

autor

Wedrychowicz H

• Szkola Glowna Gospodarstwa Wiejskiego, Grochowska 272, 03-849 Warszawa

autor

Kofta W.

Bibliografia

• BALLAS Z. K., RASMUSSEN W. L., KRIEG A. M. 1996. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157: 1840-1845.
• CONEY L., WANG B., UGEN K. E., BOYER J., MCCALLUS D., SRIKANTAN V., AGADJANYAN M., PACHUK C. J., HEROLD K., MERVA M., GILBERT L., DENG K., MOELLING K., NEWMAN M., WILIAMS W. V., WEINER D. B. 1994. Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo. Vaccine 12: 1545-1550.
• DANKO I., WOLFF J. A. 1994. Direct gene transfer into muscle. Ibid. 12: 1499-1502.
• DAVIS H. L., MICHEL M.-L., MANCINI M., SCHLEEF M., WHALEN R. G. 1994. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Ibid. 12: 1503-1509.
• ERTL H. C. J., XIANG Z. 1996. Novel vaccine approaches. J. Immunol. 156: 3579-3582.
• FYNAN E., WEBSTER R. G., FULLER D. H., HAYNES J. R., SANTORO J. C., ROBINSON H. L. 1993. DNA vaccines: Protective immunizations by parental, mucosal and gene-gun inoculations. Proc. Natl Acad. Sci. USA 90: 11478-11482.
• GRAMZINSKI R. A., MARIS D. C., DOOLAN D. 1997. Malaria DNA vaccines in Aotus monkeys. Vaccine 15: 913-915.
• HOFFMAN S. L., DOOLAN D. L., SEDEGAH M. 1997. Strategy for development of a preerythrocytic Plasmodium falciparum DNA vaccine for human use. Ibid. 15: 842-845.
• - SEDEGAH M., HEDSTROM R. C. 1994. Protection against malaria by immunization with a Plasmodium yoelli circumsporozoite protein nucleic acid vaccine. Ibid. 12: 1529-1533.
• KLINMAN D. M., YI A., BEAUCAGE S. L., CONOVER K., KRIEG A. M. 1996. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc. Natl Acad. Sci. USA 93: 2879-2883.
• KUHOBER A., PUDOLLEK H.-P., REIFENBERG K., CHISARI F. V., SCHLICHT H.-J., REIMANN J., SCHIRMBECK R. 1996. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J. Lmmunol. 156: 3687-3695.
• LIU M., HILLEMAN M. R., KURTH R. 1995. DNA vaccines - a new era in vaccinology. Ann. N. York Acad. Sci. 772: 1-184.
• MCDONNELL W. M., ASKARI F. K. 1996. DNA vaccines. N. Engl. J. Med. 334: 42-45.
• PERTMER T. M., EISENBRAUN M. D., MCCABE D., PRAYAGA S. K., FULLER D. H., HAYNES J. R. 1995. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidennal delivery of nanogram quantities of DNA. Vaccine 13: 1427-1430.
• ULMER J. B., DECK R. R„ DEWITI C. M„ FRIEDMAN A., DONNELLY J. J., LIU M. A. 1994. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Ibid. 12: 1541-1544.
• WAINE G. J„ SCOTT J. C., MCMANUS D. P., KALINNA B. H. 1997. DNA-based vaccination using Schistosoma japonicum (Asian blood-fluke) genes. Ibid. 15: 846-848.
• WEBSTER R. G., FYNAN E., SANTORO J. C., ROBINSON H. 1994. Protection of ferrets againstinfluenza challenge with a DNA vaccine to the haemagglutinin. Ibid. 12: 1495-1498.
• WYNN A. T., CHEEVER A. W., JANKOVIC D., POINDEXTER R. W., CASPAR P., LEWIS F. A., SHER A. 1995. An IL-12 - based vaccination method for preventing fibrosis induced by schistosome infection. Nature 376: 594-596.
• XU D., LIEW F. Y. 1994. Genetic vaccination against leishmaniasis. Vaccine 12: 1534-1536.
• - - 1995. Protection against leishmaniasis by injection of DNA ensoding a major surface glycoprotein, gp63, of L. major. Immunology 84: 173-176.
• YANG W., WAINE G. J., MCMANUS D. P. 1995. Antibodies to Schistosoma japonicum (asian bloodfluke) paramyosin induced by nucleic acid vaccination. Biochem. Biophys. Res. Comm. 212: 1029-1039.